Clinical Trial Update: PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for PLX038 in primary CNS tumors with MYC or MYCN amplification; Phase 1/2 studies are currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ependymoma
• Glioblastoma
• Glioma
• Medulloblastoma

Drugs mentioned

• PLX038

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Glioma, Medulloblastoma | Phase 1, Phase 2 | Status: RECRUITING